For years, science has generally considered the phosphorylation of proteins - the insertion of a phosphorous group into a protein that turns it on or off - as perhaps the factor regulating a range of cellular processes from cell metabolism to programmed cell death, comments EurekAlert.
Now, scientists from the Florida campus of The Scripps Research Institute have identified the importance of a novel protein-regulating mechanism - called sulfenylation - that is similar to phosphorylation and may, in fact, open up opportunities to develop new types of drugs for diseases such as cancer. The study was published December 11, in an advance on-line edition of the journal Nature Chemical Biology.
"With this paper, we've elevated protein sulfenylation from a marker of oxidative stress to a bona fide reversible post translational modification that plays a key regulatory role during cell signaling," said Kate Carroll, a Scripps Research associate professor who led the study, noting: "The sulfenyl modification is the new kid on the block."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze